Amount of qualified people: CDEC reviewed the uncertainty in the volume of clients with reasonably significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are categorised as obtaining gentle or moderate sickness could possibly have a signific… Read More